Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Jul 2017 Planned End Date changed from 18 Dec 2019 to 17 Jan 2019.
- 11 Jul 2017 Planned primary completion date changed from 18 Dec 2019 to 17 Jan 2019.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology